BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33854047)

  • 1. TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and anti-tumor responses.
    Caronni N; Piperno GM; Simoncello F; Romano O; Vodret S; Yanagihashi Y; Dress R; Dutertre CA; Bugatti M; Bourdeley P; Del Prete A; Schioppa T; Mazza EMC; Collavin L; Zacchigna S; Ostuni R; Guermonprez P; Vermi W; Ginhoux F; Bicciato S; Nagata S; Benvenuti F
    Nat Commun; 2021 Apr; 12(1):2237. PubMed ID: 33854047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
    Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.
    Lau CM; Tiniakou I; Perez OA; Kirkling ME; Yap GS; Hock H; Reizis B
    J Exp Med; 2018 Sep; 215(9):2265-2278. PubMed ID: 30087163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDC1 prime and are licensed by CD4
    Ferris ST; Durai V; Wu R; Theisen DJ; Ward JP; Bern MD; Davidson JT; Bagadia P; Liu T; Briseño CG; Li L; Gillanders WE; Wu GF; Yokoyama WM; Murphy TL; Schreiber RD; Murphy KM
    Nature; 2020 Aug; 584(7822):624-629. PubMed ID: 32788723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notch-Regulated Dendritic Cells Restrain Inflammation-Associated Colorectal Carcinogenesis.
    Wang L; Yu S; Chan ER; Chen KY; Liu C; Che D; Awadallah A; Myers J; Askew D; Huang AY; Maillard I; Huang D; Xin W; Zhou L
    Cancer Immunol Res; 2021 Mar; 9(3):348-361. PubMed ID: 33441309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
    Ferris ST; Ohara RA; Ou F; Wu R; Huang X; Kim S; Chen J; Liu TT; Schreiber RD; Murphy TL; Murphy KM
    Cancer Immunol Res; 2022 Aug; 10(8):920-931. PubMed ID: 35648641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
    Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
    Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy.
    Blair TC; Bambina S; Alice AF; Kramer GF; Medler TR; Baird JR; Broz ML; Tormoen GW; Troesch V; Crittenden MR; Gough MJ
    J Immunol; 2020 Jun; 204(12):3416-3424. PubMed ID: 32341058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Membrane Trafficking Proteins and Lactate Conditioning Determine Loss of Dendritic Cell Function in Lung Cancer.
    Caronni N; Simoncello F; Stafetta F; Guarnaccia C; Ruiz-Moreno JS; Opitz B; Galli T; Proux-Gillardeaux V; Benvenuti F
    Cancer Res; 2018 Apr; 78(7):1685-1699. PubMed ID: 29363545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8
    Rotman J; Heeren AM; Gassama AA; Lougheed SM; Pocorni N; Stam AGM; Bleeker MCG; Zijlmans HJMAA; Mom CH; Kenter GG; Jordanova ES; de Gruijl TD
    Clin Cancer Res; 2020 Jul; 26(14):3791-3802. PubMed ID: 32220890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung cDC1 and cDC2 dendritic cells priming naive CD8
    Si Y; Wang Y; Tian Q; Wang Q; Pollard JM; Srivastava PK; Esser-Kahn AP; Collier JH; Sperling AI; Chong AS
    Cell Rep; 2023 Oct; 42(10):113299. PubMed ID: 37864794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
    Liang Y; Hannan R; Fu YX
    Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.
    Le Gall C; Cammarata A; de Haas L; Ramos-Tomillero I; Cuenca-Escalona J; Schouren K; Wijfjes Z; Becker AMD; Bödder J; Dölen Y; de Vries IJM; Figdor CG; Flórez-Grau G; Verdoes M
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35428705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.